Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01212
|
|||||
| Drug Name |
Mitomycin
|
|||||
| Synonyms |
Ametycin; 1950/7/7; 7-Amino-9alpha-methoxymitosane; Ametycin; Ametycine; C15H18N4O5; CCRIS 414; EINECS 200-008-6; HSDB 3239; MMC; Mit-C; Mitamycin; Mito-C; Mitocin C; Mitocin-C; Mitomicina; Mitomicina [INN-Spanish]; Mitomycin (TN); Mitomycin (USP/INN); Mitomycin C; Mitomycin C (JP15); Mitomycin C from Streptomyces caespitosus; Mitomycin C,; Mitomycin C, Streptomyces caespitosus; Mitomycin C, Streptomyces caespitosus, Carrier-Free; Mitomycin [USAN:INN:BAN]; Mitomycin-C; Mitomycine; Mitomycine [INN-French]; Mitomycins; Mitomycinum; Mitomycinum C; Mitomycinum [INN-Latin]; Mitomycyna C; Mitomycyna C [Polish]; Mitosol; Mitozytrex; Muamycin; Muamycin (TN); Mutamycin; Mytomycin; Mytozytrex; NCI-C04706; NSC 26980; NSC-26980; NSC26980; RCRA waste number U010; UNII-50SG953SK6; mitomycin C
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Anxiety [ICD11: MB24.3] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H18N4O5
|
|||||
| Canonical SMILES |
CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N
|
|||||
| InChI |
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
|
|||||
| InChIKey |
NWIBSHFKIJFRCO-WUDYKRTCSA-N
|
|||||
| CAS Number |
CAS 50-07-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 334.33 | Topological Polar Surface Area | 147 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-0.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11120094
, 11120582
, 11121070
, 11121809
, 11122289
, 11147177
, 11363021
, 11365583
, 11368145
, 11371173
, 11371174
, 11373746
, 11376307
, 14899962
, 14924490
, 15249200
, 24896554
, 24896555
, 24896917
, 26759169
, 26759192
, 29224783
, 46508353
, 47440503
, 47440504
, 47589205
, 48414068
, 48416286
, 48423722
, 49854359
, 50064401
, 50111457
, 53787087
, 56310827
, 56311910
, 56312869
, 56312950
, 56313687
, 56313798
, 56313799
, 56314173
, 56314310
, 57260126
, 57322926
, 613813
, 7847275
, 8144500
, 8153525
, 87663
, 8906
|
|||||
| ChEBI ID |
ChEBI:27504
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Mitomycin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.